Last updated on April 2018

Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects


Brief description of study

This study will evaluate the effect of dose escalation of once-weekly (QW) subcutaneous (SC) OPK-8003 injections vs placebo on HbA1c absolute change from baseline at 30 weeks in subjects with type 2 diabetes mellitus (T2DM) inadequately controlled with diet and exercise alone, or treated with a stable dose of metformin.

Detailed Study Description

This clinical trial is a phase 2, double-blind dose escalation regimen of once-weekly OPK-88003 in subjects with T2DM. The trial consists of four phases: a screening/baseline phase (up to 2 weeks prior to first dose), a 30-week treatment period consisting of a dose escalation phase (8 weeks) and a target dose phase (22 weeks), and a follow-up period (4 weeks). Subjects will be randomly assigned to volume-matched OPK-88003 or placebo administered QW.

Clinical Study Identifier: NCT03406377

Contact Investigators or Research Sites near you

Start Over

Stanley Hsin-Wei Hsia

National Research Institute - Huntington Park
Huntington Park, CA United States
  Connect »

Juan Pablo Frias

National Research Institute - Wilshire
Los Angeles, CA United States
  Connect »

Kenneth Lasseter, MD

Clinical Pharmacology of Miami, LLC
Hialeah, FL United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.